AMNOG and the German Reforms: What Will Change?
Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to 17 marketsi.The implementation of AMNOG in 2011 sought to reduce drug prices and relieve the healthcare budget, yet financial pressure remains, particularly from high-priced novel agents in Hepatitis C, and Oncology. As a result, in July 2016, the German Ministry of Health put forth a legislative proposal to reduce pharmaceutical spending and perceived exorbitant prices, as well as improve the A...
Source: EyeForPharma - October 3, 2016 Category: Pharmaceuticals Authors: Preeti Patel and Sophie Schmitz Source Type: news
Alemtuzumab Comparison Data Show Some Surprises Alemtuzumab Comparison Data Show Some Surprises
New observational propensity-matched data on head-to-head comparisons of alemtuzumab with beta-interferon, fingolimod, and natalizumab show some unexpected findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 29, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Registry Data: Lemtrada More Effective than Competing MS Tx
(MedPage Today) -- Better than fingolimod or interferon; comparable to natalizumab (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 17, 2016 Category: Journals (General) Source Type: news
ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)
(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 16, 2016 Category: Consumer Health News Source Type: news
Multiple Sclerosis May Rebound When Patients Stop Fingolimod Multiple Sclerosis May Rebound When Patients Stop Fingolimod
In this viewpoint, Dr Barclay discusses a series of five patients with rebound whose cases were consistent with others in the literature.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 19, 2016 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news
Long-term Treatment With Fingolimod in MSLong-term Treatment With Fingolimod in MS
The results of this study support a continued beneficial effect of long-term fingolimod therapy in patients with relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models
(JCI Journals) In this issue of JCI Insight, May Han of Stanford University and colleagues tested the hypothesis that genetic variants of the cell surface receptor that responds to S1P, S1PR1, may influence the efficacy of fingolimod. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 16, 2016 Category: Global & Universal Source Type: news
Real-world data favor dimethyl fumarate, fingolimod for MS
VANCOUVER – Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative effectiveness... (Source: Family Practice News)
Source: Family Practice News - June 14, 2016 Category: Primary Care Source Type: news
Real-world data favor dimethyl fumarate, fingolimod for MS
VANCOUVER – Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative effectiveness... (Source: Clinical Neurology News)
Source: Clinical Neurology News - June 14, 2016 Category: Neurology Source Type: news
Relapses Rebound in Patients With MS Stopping FingolimodRelapses Rebound in Patients With MS Stopping Fingolimod
As seen with natalizumab, a new study shows patients may experience rebound in relapses after stopping fingolimod. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Real risk of rebound syndrome following fingolimod cessation for MS
Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs. (Source: MedWire News)
Source: MedWire News - May 4, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news
Patients May Rebound After Stopping Gilenya (CME/CE)
(MedPage Today) -- Severe rebound syndrome seen in 10% of cases after discontinuation (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 4, 2016 Category: Neurology Source Type: news
Fewer new lesions, side effects differentiate fingolimod from dimethyl fumarate
VANCOUVER – Multiple sclerosis patients discontinued treatment and relapsed earlier with dimethyl fumarate (Tecfidera) than with fingolimod (Gilenya), and had more gadolinium-enhancing lesions at 12... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 28, 2016 Category: Neurology Source Type: news
Rituximab outperforms fingolimod after natalizumab switch
Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests. (Source: MedWire News)
Source: MedWire News - April 26, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study included patients infected with JC virus, which is present in approximately 50% of the general population. While the virus generally causes no problems under normal circumstances, it can cause progressive multifocal leukoencephalopathy (PML), a serious demyelinating disease of the brain, in patients with immune deficiencies due to disease or immunosuppressant drugs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2016 Category: Science Source Type: news
